Tianjin Lisheng Pharmaceutical Co., Ltd. Class A

As of June 30, 2026, Tianjin Lisheng Pharmaceutical Co., Ltd. Class A carries a market capitalization of 4.38B, placing it among publicly traded companies globally. Its enterprise value stands at 2.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Tianjin Lisheng Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for October 26, 2026.

As of June 30, 2026, Tianjin Lisheng Pharmaceutical Co., Ltd. Class A has 308.96M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Tianjin Lisheng Pharmaceutical Co., Ltd. Class A maintains a current ratio of 4.76, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Tianjin Lisheng Pharmaceutical Co., Ltd. Class A recorded an income tax benefit of -10.91M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 23, 2026, Tianjin Lisheng Pharmaceutical Co., Ltd. Class A's stock has declined approximately 33.18% over the past 52 weeks. The 50-day moving average sits at 14.08, while the 200-day moving average is 16.20.

As of June 30, 2026, Tianjin Lisheng Pharmaceutical Co., Ltd. Class A holds 2.30B in cash and equivalents against 12.94M in total debt, resulting in a net debt position of -1.25B. Total book value stands at 4.49B, with working capital of 2.51B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Tianjin Lisheng Pharmaceutical Co., Ltd. Class A paid dividends of 0.76 per share.

Tianjin Lisheng Pharmaceutical Co., Ltd. Class A's most recent stock split took place on April 28, 2026 with a 5:6 split ratio.